Thus, BsAb can be used as a component of the immunocytokine complex for the delivery of IFN-β to ErbB2-associated tumor cells, which would avoid the manifestation of side effects when IFN-β is administered as a single therapeutic. The gene discussed is ERBB2; the disease is neoplasm.